Publications by authors named "Tim Bourne"

Claim this Profile
C
Corrigendum: An orally available small molecule that targets soluble TNF to deliver anti-TNF biologic-like efficacy in rheumatoid arthritis.
Alexander Vugler, James O'connell, Mai Anh Nguyen, Dietmar Weitz, Thomas Leeuw, Tim Bourne

Front Pharmacol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential roles of CTP synthetases CTPS1 and CTPS2 in cell proliferation.
Norbert Minet, Anne-Claire Boschat, Rebecca Lane, David Laughton, Philip Beer, Tim Bourne

Life Sci Alliance· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Target occupancy biomarker assay development using a conformation-selective antibody against small-molecule-bound TNF.
Elizabeth S Hickford, James O'Connell, Alison Maloney, Peter Florian, Geoffrey I Johnston, Tim Bourne

Bioanalysis· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transitioning EPMA applications in a large multisite teaching hospital.
Geeth Silva, Graeme Hall, Aaron Vogel, Tim Bourne, Gang Xu

BMJ Open Qual· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An orally available small molecule that targets soluble TNF to deliver anti-TNF biologic-like efficacy in rheumatoid arthritis.
Alexander Vugler, James O'Connell, Mai Anh Nguyen, Dietmar Weitz, Thomas Leeuw, Tim Bourne

Front Pharmacol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MTHFD2 is a metabolic checkpoint controlling effector and regulatory T cell fate and function.
Ayaka Sugiura, Gabriela Andrejeva, Kelsey Voss, Darren R Heintzman, Xincheng Xu, Tim Bourne

Immunity· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Codeveloping an effective EMPA to maturity in an acute NHS Trust: an implementer report.
Geeth Silva, Tim Bourne, Graeme Hall, Shriyam Patel, Mohammed Qasim Rauf

BMJ Health Care Inform· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peri-operative Variables Associated With Prolonged Intensive Care Stay Following Cytoreductive Surgery for Ovarian Cancer.
Anna Collins, Stephanie Spooner, Jonathan Horne, Mira Chainrai, Franscois Runau, Tim Bourne

Anticancer Res· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structural insights into the disruption of TNF-TNFR1 signalling by small molecules stabilising a distorted TNF.
David McMillan, Carlos Martinez-Fleites, John Porter, David Fox, Rachel Davis, Tim Bourne

Nat Commun· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A conformation-selective monoclonal antibody against a small molecule-stabilised signalling-deficient form of TNF.
Daniel J Lightwood, Rebecca J Munro, John Porter, David McMillan, Bruce Carrington, Tim Bourne

Nat Commun· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impaired lymphocyte function and differentiation in CTPS1-deficient patients result from a hypomorphic homozygous mutation.
Emmanuel Martin, Norbert Minet, Anne-Claire Boschat, Sylvia Sanquer, Steicy Sobrino, Tim Bourne

JCI Insight· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Small molecules that inhibit TNF signalling by stabilising an asymmetric form of the trimer.
James O'Connell, John Porter, Boris Kroeplien, Tim Norman, Stephen Rapecki, Tim Bourne

Nat Commun· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of an Inhaled IL-13 Antibody Fragment in a Model of Chronic Asthma.
Daniel Lightwood, Markus Tservistas, Monique Zehentleitner, Kaushik Sarkar, Alison Turner, Tim Bourne

Am J Respir Crit Care Med· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling.
Stevan Shaw, Tim Bourne, Chris Meier, Bruce Carrington, Rich Gelinas

MAbs· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Collagen II antibody-induced arthritis in Tg1278TNFko mice: optimization of a novel model to assess treatments targeting human TNFα in rheumatoid arthritis.
Adrian Richard Moore, Sarah Allden, Tim Bourne, Maria C Denis, Ksanthi Kranidioti

J Transl Med· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "The Discovery, Engineering and Characterisation of a Highly Potent Anti-Human IL-13 Fab Fragment Designed for Administration by Inhalation" [J. Mol. Biol. 425 (2013), 577-593].
Daniel Lightwood, Victoria O'Dowd, Bruce Carrington, Vaclav Veverka, Mark D Carr, Tim Bourne

J Mol Biol· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The discovery, engineering and characterisation of a highly potent anti-human IL-13 fab fragment designed for administration by inhalation.
Daniel Lightwood, Victoria O'Dowd, Bruce Carrington, Vaclav Veverka, Mark D Carr, Tim Bourne

J Mol Biol· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The use of surrogate antibodies to evaluate the developmental and reproductive toxicity potential of an anti-TNFalpha PEGylated Fab' monoclonal antibody.
Ian Wakefield, Sue Stephens, Roly Foulkes, Andrew Nesbitt, Tim Bourne

Toxicol Sci· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A PEGylated Fab' fragment against tumor necrosis factor for the treatment of Crohn disease: exploring a new mechanism of action.
Tim Bourne, Gianluca Fossati, Andrew Nesbitt

BioDrugs· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents.
Andrew Nesbitt, Gianluca Fossati, Marianne Bergin, Paul Stephens, Sue Stephens, Tim Bourne

Inflamm Bowel Dis· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Essential role for CD103 in the T cell-mediated regulation of experimental colitis.
Oliver Annacker, Janine L Coombes, Vivianne Malmstrom, Holm H Uhlig, Tim Bourne

J Exp Med· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis